1. Medtech Insight
  2. >>Geography
  3. >>Europe

Orphan Devices Pilot Program Tackles Parliament’s Proposal Head On

 
• By Amanda Maxwell

The need for the EU to foster the development of orphan devices, intended for smaller patient populations with less commercial promise, is well documented. At last, action is starting.

babies
Infants Are Among Those Who Benefit From Orphan Devices For Rare Diseases • Source: Shutterstock

The European Medicines Agency has introduced a pilot program for expert panels to assist with the development and evaluation of orphan medical devices.

Challenges Of Orphan Devices Reaching Children

The guidance document, MDCG 2024-10 Clinical evaluation of orphan medical devices, points out that in many cases, orphan devices are intended for use solely or predominantly in minors and paediatric populations, and/or in emergency situations.

But, it says, generating clinical data efficiently for small patient populations is difficult, especially for vulnerable groups due to ethical and regulatory requirements, including infants and children. 

Compliance with MDR requirements, including certification, it says, can lead to increased and unpredictable financial costs, hindering manufacturers from placing orphan devices on the EU market due to low sales not covering expenses.

This program provides free advice to selected manufacturers and notified bodies on orphan device status and the data needed for...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Europe

Have Your Say On EU Digital Regulation Overkill

 
• By Amanda Maxwell

European Commission is expected to have tsunami of responses, including from medtech stakeholders to its public consultation. The US is already intensely interested in developments.

Breast Tissue Regeneration: Tensive’s Journey To Restore ‘Wholeness’ For Cancer Survivors

 
• By Natasha Barrow

Medtech Insight spoke with Sanjay Kakkar, Tensive CEO, about the firm’s breast tissue regeneration implant and its surgical benefits, including a reduced operation time of 74 minutes. He anticipates regulatory approval for Regenera in early 2027.

Asabys Partners Talks SafeHeal €10M Investment At LSI Europe

 
• By Natasha Barrow

SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.

EU Data Act Applies From Today: But Medtech Wants Delay

 
• By Amanda Maxwell

The unwieldy application demands of the EU’s bunch of interconnected data regulations are creating headaches for the medtech industry.

More from Geography

Mental Health The Focus Of Upcoming Digital Health Advisory Committee Meeting

 
• By Brian Bossetta

The US FDA will hold a public meeting of its Digital Health Advisory Committee in November to focus on generative AI-enabled medical devices to treat mental health.

Blood Sugar Spike Risk Leads To Recall Of Tandem Insulin Pumps

 
• By Brian Bossetta

Tandem Diabetes Care initiated a recall last month of several t:slim X2 insulin pumps due to a “malfunction 16” error that can cause the pumps to shut down. The problem is triggered by wiring within the device speaker.

FTC’s New Healthcare Division Chief Is Former Antitrust Prosecutor

 
• By Malcolm Spicer

Emma Mittelstaedt Burnham prosecuted antitrust violations in healthcare sector in her previous work at DoJ, including leading investigation into antitrust cartels in the generic pharmaceutical industry.